Skip to main content
Premium Trial:

Request an Annual Quote

A Surprise

Premium

Novartis' kidney cancer drug Afinitor has been shown to prevent the progression of breast cancer in a new study, reports Bloomberg's Simeon Bennett. The trial showed that Afinitor more than doubled, to 6.9 months, the time to progression in women whose breast tumors had spread after treatment, compared to 2.8 months in women who took Pfizer's breast cancer drug Aromasin, Bennett says. The trial, which Novartis plans to use in applying for regulatory approval for a breast cancer indication for Afinitor, was presented at a cancer conference in Stockholm this week. Analysts say that European regulators are likely to approve the new indication based on the study's results, though the FDA may want to see longer-term breast cancer data before approval. "Afinitor, which is already approved in the US as a treatment for cancers of the kidney and pancreas, as well as non-cancerous brain tumors, blocks a protein called mTOR that some cancer cells require to grow and multiply," Bennett says. "Novartis is also testing the drug in patients with other types of breast cancer, as well as lymphoma and stomach and liver cancer."

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.